

Neuro-immune interaction during development of pulmonary fibrosis

Ananya Jain and Jerry Yu*

Pulmonary Division, Department of Medicine, University of Louisville, Louisville, KY, USA

Abstract

Pulmonary neuroendocrine cells are widely distributed throughout the airway mucosa of mammals. They may exist as solitary cells or aggregate to form Neuro-Epithelial Bodies (NEBs), which are important in early lung development. Pulmonary Fibrosis (PF) is a devastating disease caused by various pulmonary insults. The lung repair after injury is a complex process which involves a network of interactions among mediators, cytokines, and growth factors of inflammatory, endothelial, and epithelial cell origin. These interactions lead to lung remodeling, deposition of collagen, limitation of gas exchange, and dyspnea. The vagus nerve is related to each component of this network. Increasing evidence indicates that the NEB-Vagal System (NVS) plays an important role in neuro-immune interactions. NEBs are richly innervated and connect with the central nervous system through vagal afferent and efferent nerves. Stimulation of the vagus nerve in patients significantly increases the levels of TGF- β in plasma, a substance that promotes fibrosis. Based on current information, lung injury may activate the NVS, which then leads to PF via fibrogenic cells and molecules. Therefore, over-activation of the NVS could contribute to disease progression.

Introduction

Pulmonary Fibrosis (PF) can result from various lung injuries (autoimmune diseases, drugs, occupational exposures). PF of unknown etiology manifests as a group of diseases classified as Idiopathic Pulmonary Fibrosis (IPF) [1]. Although the prevalence of IPF ranges from 6-14.6 per 100,000 people [2], it is uniformly fatal. The median survival is 3-5 years after diagnosis [3]. Despite extensive research efforts, the understanding of the underlying disease mechanisms is limited, and there exists no effective treatment. Growing evidence indicates that the neuro-endocrine system controls immune and cellular responses, so activation of the NVS may promote PF. This mini-review presents available information to support this hypothesis.

PF may result from chronic inflammation in rheumatoid arthritis, and in IPF, through profibrotic mechanisms with no inflammation. In IPF, repetitive injury to alveolar epithelium causes fibroblast recruitment and transformation to a myofibroblast phenotype. Myofibroblasts are fibrogenic cells that release abundant Extracellular Matrix (ECM) containing collagen and fibronectin into the lung interstitium, which leads to PF. This process is enhanced by fibrogenic cytokines and cells, and is regulated by the NVS (NEB-Vagal-System).

The vagus nerve

The lung is innervated mainly by the vagus nerve, which is involved in the pathogenesis of asthma, COPD, ARDS, lung cancer, and potentially the development of PF [4]. The nervous and immune systems interact via shared ligands and receptors. For example, neurons express pro-inflammatory cytokines [5] and immune cells express neural mediators and their receptors [6]. Stimulation of vagal afferents exerts anti-inflammatory effects via Acetylcholine (ACh) released by vagal efferents [7]. Electrical stimulation of vagal efferents during endotoxemia inhibits TNF- α synthesis and prevents endotoxemic shock [8]. During lung injury and inflammation, tachykinin levels in nociceptive afferents increase [9] and a variety of neural, epithelial,

endothelial, and phagocytic cells produce inflammatory cytokines, mediators, neuropeptides and other substances, like reactive oxygen species [10,11]. These agents activate vagal sensory afferents [12] to cause local (e.g. release of neuropeptides) or central reflexes to stimulate ECM production via T-cells, macrophages and fibroblasts. Stimulation of the vagus nerve in patients with depression significantly increased levels of transforming growth factor beta (TGF- β), a substance which promotes fibrosis [13], while vagotomy eliminated the drug-induced activation of TGF- β in cerebrospinal fluid [14]. ACh can also activate M receptors to promote fibroblast proliferation in the lung [15]. Additionally, maternal nicotine exposure increased levels of collagen mRNA in pulmonary fibroblasts via α -7nAChR [16]. In inflammatory bowel diseases, vagotomy promotes type-1 helper T (Th₁) cytokines but inhibits type-2 helper T (Th₂) cytokines. In addition, vagal denervation decreases collagen deposition in the lung (Trichrome stain and ELISA), pulmonary consolidation, and the Ashcroft score [17].

The NEBs

Pulmonary Neuroendocrine Cells (PNECs) are widely distributed throughout the airway mucosa of mammals. They may aggregate to form NEBs, which are innervated by vagal, spinal, and parabrachial nerves [18]. NEBs are connected to the central nervous system via the sympathetic nerve and nociceptors (C fiber receptors and high threshold A delta fiber receptors) in the vagus nerve [19]. In addition, NEBs are in direct contact with sensory afferents that immune-reactive for substance P (SP) [18] and may cause neurogenic airway inflammation [19]. PNECs/NEBs can release many bioactive substances with growth factors and mitogenic properties, such as bombesin/

Correspondence to: Jerry Yu, Division of Pulmonary Medicine, University of Louisville, ACB-3, 550 S. Jackson St, Louisville, KY 40292, E-mail: j0yu0001@louisville.edu

Received: July 26, 2017; **Accepted:** August 24, 2017; **Published:** August 28, 2017

Gastrin-Releasing Peptide (GRP), Calcitonin Gene-Related Peptide (CGRP), and 5-hydroxytryptamine (5-HT) [20]. These substances play an important role in lung morphogenesis, which is why NEBs prevail in fetal and neonatal lungs [21]. Morphogenesis is a process much like tissue remodeling, which is an important step in PF. NEB secretory products, such as bombesin/GRP, may exert airway remodeling effects, including proliferation of fibroblasts, and epithelial and smooth muscle cells [22]. Bombesin additionally induces alveolar wall thickening and myofibroblast proliferation, as demonstrated by intraperitoneal bombesin injection in mice [23]. 5-HT stimulates collagen synthesis by fibroblasts, which can be attenuated by 5-HT antagonists [24]. Furthermore, NEBs are thought to be stem cell niches [25], protective microenvironments for stem cells. For example, after naphthalene-induced injury, airway epithelial cells regenerate from cells within NEBs. Abnormalities of PNECs/NEBs are found in many human diseases, including congenital pneumonia, bronchopulmonary dysplasia, Wilson-Mikity syndrome (WMS, pulmonary dysmaturity), congenital central hypoventilation syndrome, sudden infant death syndrome, neuro-endocrine hyperplasia of infancy, cystic fibrosis, asthma, and pulmonary hypertension [20]. For example, in bronchopulmonary dysplasia, a disease in which airway epithelium is repeatedly injured, significant hyperplasia of PNECs/NEBs occurs. Altogether, it is clear that NEBs are involved in neuroendocrine interaction and respond to lung injury. In bleomycin-induced PF mice, the number and size of NEBs increased significantly within two weeks, supporting the hypothesis that they play an important role in the pathogenesis of PF [26].

Cytokines

Cytokines, chemokines, and their receptors are significantly up-regulated in patients with IPF [27]. For example, TGF- β activation plays a major role in myofibroblast transformation, and its overexpression leads to PF [28]. This process can be prevented by inactivating the TGF- β transgene [29]. Transient overexpression of Interleukin-1 β (IL-1 β) in lung epithelial cells causes acute inflammation and tissue destruction, followed by production of fibrogenic cytokines and interstitial fibrosis [30], whereas inhibition of IL-1 β alleviates fibrosis [31]. Interleukin 4 (IL-4) is also an important molecule in fibrogenesis, since it acts on fibroblast receptors to regulate proliferation, collagen synthesis, and differentiation into myofibroblasts [32-34]. Expression of IL-4 receptors increases in bleomycin-induced lung injury [35]. TNF may also play a significant role in TGF- β production and PF [36], for example, bleomycin administration caused significantly less PF in TNF-deficient mice than in wild-type mice [37]. Vagotomy can also attenuate PF by suppressing the production of fibrogenic cytokines (TGF- β and IL-4), which stimulate fibroblast differentiation into myofibroblasts [17].

Fibrogenic cells

In the adaptive immune response, various CD4⁺ T cell subsets are distinct. For example, CD4⁺ progenitor T cells can be further categorized into Th₁, Th₂ and regulatory T (Treg) cells. Up-regulation of Th₂ cytokines and down-regulation of Treg cytokines are associated with fibrosis. IPF is usually characterized by a shift from Th₁ to Th₂ cytokine expression [38]. Much like the Th₁/Th₂ dichotomy, there are also two major types of macrophages. M₁ macrophages are pro-inflammatory (via LPS, INF- γ , and Th₁ associated cytokines), whereas M₂ macrophages are pro-fibrotic (via glucocorticoids, TGF- β , and Th₂ associated cytokines) [39]. Neuropeptides, vasoactive intestinal polypeptide, and pituitary adenylate cyclase-activating polypeptide are all potent immune-modulators. They induce a switch from Th₁

to Th₂ immune responses, which then leads to the differentiation of monocytes into pro-fibrotic M₂ macrophages [39]. Modulation of macrophage phenotypes can prevent PF in bleomycin-induced or TGF- β -upregulated murine PF models [40]. For example, treatment with serum amyloid protein mitigates fibrosis by decreasing the number of M₂ macrophages and fibrocytes. Vagotomy also decreases the number of fibrogenic cells (myofibroblasts and M₂ macrophages) in the lung tissue and bronchoalveolar lavage fluid, supporting the hypothesis that the vagus nerve may promote the proliferation of fibrogenic cells [17].

Conclusion

Neuro-immune interaction influences the pathophysiological processes of various diseases, yet, is still an evolving area of research. In this article, we have illustrated that the interaction occurs at different levels (systemic, cellular, and molecular) and provided evidence to support the hypothesis that the NVS plays an important role in the pathogenesis of PF. More specifically, PF develops as the number and size of NEBs, pro-fibrogenic cytokines, and cells also increase, as evidenced in mice intravenously injected with bleomycin. This pro-fibrotic process can be attenuated by interrupting the NVS. Further delineation of the underlying mechanisms will potentially lead to novel strategies to treat PF.

References

1. Travis WD, Costabel U, Hansell DM, King TE, Jr, Lynch DA, et al. (2013) An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 188: 733-748. [Crossref]
2. American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J Respir Crit Care Med* 165: 277-304. [Crossref]
3. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL, et al. (1994) Determinants of survival in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 149: 450-454. [Crossref]
4. Song N, Liu J, Moldoveanu B, Guardiola J, Perez R, et al. (2012) The vagus nerve and pulmonary disease. *Fudan Univ J Med Sci* 39: 117-123.
5. Breder CD, Dinarello CA, Saper CB (1988) Interleukin-1 immunoreactive innervation of the human hypothalamus. *Science* 240: 321-324. [Crossref]
6. Lai JP, Douglas SD, Ho WZ (1998) Human lymphocytes express substance P and its receptor. *J Neuroimmunol* 86: 80-86. [Crossref]
7. Tracey KJ (2002) The inflammatory reflex. *Nature* 420: 853-859. [Crossref]
8. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, et al. (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* 405: 458-462. [Crossref]
9. Fischer A, McGregor GP, Saria A, Philippin B, Kummer W (1996) Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation. *J Clin Invest* 98: 2284-2291. [Crossref]
10. Lee LY, Pisarri TE (2001) Afferent properties and reflex functions of bronchopulmonary C-fibers. *Respir Physiol* 125: 47-65. [Crossref]
11. Yu J, Lin S, Zhang J, Otmishi P, Guardiola JJ (2007) Airway nociceptors activated by pro-inflammatory cytokines. *Respir Physiol Neurobiol* 156: 116-119. [Crossref]
12. Yu J (2009) Airway receptors and their reflex function—invited article. *Adv Exp Med Biol* 648: 411-420. [Crossref]
13. Corcoran C, Connor TJ, O'Keane V, Garland MR (2005) The effects of vagus nerve stimulation on pro- and anti-inflammatory cytokines in humans: a preliminary report. *Neuroimmunomodulation* 12: 307-309. [Crossref]
14. Fujikawa T, Fujita R, Iwaki Y, Matsumura S, Fushiki T, et al. (2010) Inhibition of fatty acid oxidation activates transforming growth factor-beta in cerebrospinal fluid and decreases spontaneous motor activity. *Physiol Behav* 101: 370-375. [Crossref]

15. Profita M, Bonanno A, Siena L, Bruno A, Ferraro M, et al. (2009) Smoke, choline acetyltransferase, muscarinic receptors, and fibroblast proliferation in chronic obstructive pulmonary disease. *J Pharmacol Exp Ther* 329: 753-763. [[Crossref](#)]
16. Sekhon HS, Keller JA, Proskocil BJ, Martin EL, Spindel ER (2002) Maternal Nicotine Exposure Upregulates Collagen Gene Expression in Fetal Monkey Lung . Association with alpha 7 Nicotinic Acetylcholine Receptors. *Am J Respir Cell Mol Biol* 26: 31-41. [[Crossref](#)]
17. Song N, Liu J, Shaheen S, Du L, Proctor M, et al. (2015) Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice. *Sci Rep* 5: 13419.
18. Adriaensen D, Brouns I, Pintelon I, De Proost I, Timmermans JP (2006) Evidence for a role of neuroepithelial bodies as complex airway sensors: comparison with smooth muscle-associated airway receptors. *J Appl Physiol* 101: 960-970. [[Crossref](#)]
19. Yu J, Lin SX, Zhang JW, Walker JF (2006) Pulmonary nociceptors are potentially connected with neuroepithelial bodies. *Adv Exp Med Biol* 580: 301-306. [[Crossref](#)]
20. Cutz E, Yeger H, Pan J (2007) Pulmonary neuroendocrine cell system in pediatric lung disease-recent advances. *Pediatr Dev Pathol* 10: 419-435. [[Crossref](#)]
21. Pan J, Yeger H, Cutz E (2004) Innervation of pulmonary neuroendocrine cells and neuroepithelial bodies in developing rabbit lung. *J Histochem Cytochem* 52: 379-389. [[Crossref](#)]
22. Johnson DE, Georgieff MK (1989) Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy. *Am Rev Respir Dis* 140: 1807-1812. [[Crossref](#)]
23. Ashour K, Shan L, Lee JH, Schlicher W, Wada K, et al. (2006) Bombesin inhibits alveolarization and promotes pulmonary fibrosis in newborn mice. *Am J Respir Crit Care Med* 173: 1377-1385. [[Crossref](#)]
24. Fabre A, Marchal-Somme J, Marchand-Adam S, Quesnel C, Borie R, et al. (2008) Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. *Eur Respir J* 32: 426-436. [[Crossref](#)]
25. Giangreco A, Reynolds SD, Stripp BR (2002) Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. *Am J Pathol* 161: 173-182. [[Crossref](#)]
26. Liu J, Song N, Tian S, Yu J (2014) Neuroepithelial body increases in bleomycin-treated mice. *Respir Physiol Neurobiol* 193: 52-54. [[Crossref](#)]
27. Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, et al. (2001) ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 164: 2239-2242. [[Crossref](#)]
28. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J (1997) Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. *J Clin Invest* 100: 768-776. [[Crossref](#)]
29. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW, Yehualaeshet T, Lu B, Flavell RA, Milbrandt J, Homer RJ, Elias JA (2004) Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. *J Exp Med* 200: 377-389. [[Crossref](#)]
30. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J (2001) Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. *J Clin Invest* 107: 1529-1536. [[Crossref](#)]
31. Piguet PF, Vesin C, Grau GE, Thompson RC (1993) Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. *Cytokine* 5: 57-61. [[Crossref](#)]
32. Ando M, Miyazaki E, Fukami T, Kumamoto T, Tsuda T (1999) Interleukin-4-producing cells in idiopathic pulmonary fibrosis: an immunohistochemical study. *Respirology* 4: 383-391. [[Crossref](#)]
33. Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH (2003) Dual roles of IL-4 in lung injury and fibrosis. *J Immunol* 170: 2083-2092. [[Crossref](#)]
34. Postlethwaite AE, Holness MA, Katai H, Raghov R (1992) Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. *J Clin Invest* 90: 1479-1485. [[Crossref](#)]
35. Baecher-Allan CM, Barth RK (1993) PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis. *Reg Immunol* 5: 207-217. [[Crossref](#)]
36. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, et al. (1998) Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. *Am J Pathol* 153: 825-832. [[Crossref](#)]
37. Piguet PF, Kaufman Step, Barazzzone Cons, Muller Matt, Ryffel Bern, et al. (1997) Resistance of TNF/LTa double deficient mice to bleomycin-induced fibrosis. *International Journal of Experimental Pathology* 78: 43-48. [[Crossref](#)]
38. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med* 18: 1028-1040. [[Crossref](#)]
39. Goerd S, Orfanos CE (1999) Other functions, other genes: alternative activation of antigen-presenting cells. *Immunity* 10: 137-142. [[Crossref](#)]
40. Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, et al. (2011) TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. *Int J Biochem Cell Biol* 43: 154-162. [[Crossref](#)]